Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma
2028. ápr. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Matrix‑stiffness‑triggered mechanotransduction fuels hepatocellular carcinoma proliferation through Hippo‑orchestrated ANKRD1‑PRMT5 complex‑driven arginine methylome remodeling.
2026. okt. 24.· Military Medical Research· PUBMED
Publikáció
Role of PRMT5 in regulating ferritinophagy during Mycobacterium tuberculosis infection.
2026. szept. 22.· PLoS pathogens· PUBMED
Publikáció
Targeting PRMT5 with indole-based arylsulfonylhydrazides: a novel epigenetic strategy for the treatment of acute and chronic leukemia.
2026. szept. 15.· American journal of cancer research· PUBMED
Publikáció
Targeting the PRMT5-CBX8 axis overcomes dual barriers of CD8⁺ T cell exclusion and tumor stemness for sensitizing TNBC to anti-PD-1 therapy.
2026. szept. 14.· Oncogene· PUBMED
Publikáció
Cryo-EM structure-based discovery of etravirine as a specific inhibitor of PRMT5/pICln protein-protein interaction for prostate cancer treatment.
2026. szept. 8.· Journal of enzyme inhibition and medicinal chemistry· PUBMED
Publikáció
PRMT5 Inhibition by SCR-6920 Downregulates HIF-1α and Exhibits Synergistic Antitumor Activity with Bevacizumab in Ovarian Cancer.
2026. szept. 2.· Molecular cancer therapeutics· PUBMED
Publikáció
Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam.
2026. szept. 1.· Cancer research communications· PUBMED
Publikáció
MTAP loss in non-small-cell lung Cancer and beyond: Therapeutic targeting of the MAT2A-PRMT5 axis.
2026. aug. 29.· Cancer treatment reviews· PUBMED
Publikáció
PRDX1 drives colorectal cancer progression and immune microenvironment remodeling by facilitating PRMT5 nuclear translocation to activate Wnt/β-catenin signaling.
2026. aug. 27.· International journal of biological macromolecules· PUBMED
Vizsgálat
BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
2026. aug. 21.· PHASE1_PHASE2 · RECRUITING· CTGOV
Publikáció
Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-Null Non-Small Cell Lung Cancer.
2026. aug. 17.· Biomolecules· PUBMED
Publikáció
Systemic administration of the PRMT5 inhibitor GSK3326595 does not induce overt cardiotoxicity in the murine heart.
2026. aug. 15.· Journal of molecular and cellular cardiology plus· PUBMED
Publikáció
Flavokawain A inhibits high glucose-induced malignant progression of lung cancer cells by suppressing PRMT5-mediated PTEN neddylation and nuclear translocation.
2026. aug. 14.· Oncology letters· PUBMED
Publikáció
PPM1B suppresses cervical carcinoma invasion by dephosphorylating MYPT1 at Thr853 and inactivating the PRMT5 epigenetic axis.
2026. aug. 8.· European journal of cell biology· PUBMED
Publikáció
Targeting PRMT5 to reshape the immune microenvironment and reverse Trop2 ADC resistance in triple-negative breast cancer.
2026. aug. 4.· Cellular oncology (Dordrecht, Netherlands)· PUBMED
Publikáció
Discovery of novel cereblon-recruiting PRMT5 degraders with in vivo efficacy against triple-negative breast cancer.
2026. aug. 1.· European journal of medicinal chemistry· PUBMED
Vizsgálat
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
2026. júl. 27.· PHASE2 · RECRUITING· CTGOV
Publikáció
PRMT5 promotes psoriatic inflammation through mediating dimethylation of p65 in keratinocytes.
2026. júl. 10.· Molecular medicine (Cambridge, Mass.)· PUBMED
Publikáció
PRMT5 as a Key Driver of Stemness and Metastatic Potential in Triple-Negative Breast Cancer.
2026. jún. 20.· Biomolecules· PUBMED
Publikáció
PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?
2026. jún. 19.· Annals of oncology : official journal of the European Society for Medical Oncology· PUBMED
Publikáció
PCK2-Mediated PQBP1 Lactylation Promotes Asthmatic Inflammation through PRMT5 Inhibition.
2026. jún. 19.· Research (Washington, D.C.)· PUBMED
Publikáció
PRMT5-mediated methylation of LKB1 controls PD-L1 expression in NSCLC.
2026. jún. 10.· Biomedical journal· PUBMED
Publikáció
PKA signaling modulates PRMT5/hnRNP A1-mediated IRES translation and dictates responses to mTOR inhibition in glioblastoma.
2026. jún. 5.· Journal of neuro-oncology· PUBMED
Publikáció
PRMT5 is a prognostic-related biomarker associated with the tumor immune microenvironment in lung adenocarcinoma.
2026. jún. 5.· Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico· PUBMED
Publikáció
LKB1 inactivation elicits an NNMT-mediated methyl sink and confers dependence on PRMT5 in lung cancer.
2026. jún. 2.· Cell reports· PUBMED
Publikáció
Structure-based discovery of a highly potent, selective, and brain-penetrant MTA-cooperative PRMT5 synthetic lethal inhibitor for the treatment of glioblastoma.
2026. máj. 21.· European journal of medicinal chemistry· PUBMED
Publikáció
Arginine methylation of human DNA topoisomerase I by PRMT5 facilitates DNA relaxation.
2026. máj. 20.· Nucleic acids research· PUBMED
Publikáció
The Discovery of TNG456: A Highly Potent, Selective, Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers.
2026. máj. 18.· Journal of medicinal chemistry· PUBMED
Publikáció
Inhibition of PRMT5 sensitizes B-cell non-Hodgkin lymphoma cells to both intrinsic and extrinsic apoptotic cell death.
2026. máj. 16.· Blood neoplasia· PUBMED